Clinical trial · Interventional
A Trial Of SU14813 In Patients With Advanced Solid Malignancies
A Phase I Dose Escalating Study Of SU014813 In Patients With Solid Tumors Not Amenable To Conventional Therapy
NCT00982267CI-TRIAL-00005340completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to define the Maximum tolerated dose of SU14813 when administered as single agent in patients with solid tumors.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neoplasms | Neoplasm | ONTOLOGY_EXACT | 0.90 |
| Solid Tumors | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| SU014813 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- SU014813
- interventionNames
- Drug: SU014813
Primary outcomes (1)
- measure
- Maximum Tolerated Dose (MTD)
- timeFrame
- 18-Nov-2008
Secondary outcomes (4)
- measure
- Determine the recommended Phase 2 dose (RP2D)
- timeFrame
- 18-Nov-2008
- measure
- Preliminary information on SU014813 anti-tumor effect;
- timeFrame
- 18-Nov-2008
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with a histologically proven advanced solid malignancy for which no recognized therapy was available or for which standard therapy had failed * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Serum albumin ≥3.0 g/dL and adequate haemopoietic, renal and liver function Exclusion Criteria: * Chemotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) or radiotherapy or an investigational agent within 4 weeks before the start of study treatment * Subjects had to have recovered from all prior treatment toxicities, except alopecia, and from any major surgery.
References
Publications (1)
- DERIVEDFiedler W, Giaccone G, Lasch P, van der Horst I, Brega N, Courtney R, Abbattista A, Shalinsky DR, Bokemeyer C, Boven E. Phase I trial of SU14813 in patients with advanced solid malignancies. Ann Oncol. 2011 Jan;22(1):195-201. doi: 10.1093/annonc/mdq313. Epub 2010 Jul 6. PMID 20605934